Targeting NF-kB Signaling using a Novel Inhibitor in DLBCL

Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell malignancy that can be categorized by cell of origin, molecular features and reoccurring mutations. The transcription factor “NF-κB” plays a key role in cell survival, inflammation and immune responses; in cancer it promotes malignant cell proliferation.Targeting pathways such as the NF-κB is a viable option to treat B-cell malignancies. A novel NF-κB inhibitor was evaluated in DLBCL cell lines (OCI-LY3, RI-1, and Pfeiffer). The NF-κB inhibitor showed cytotoxic effects in DLBCL cells, especially those dependent on NF-κB.https://digitalcommons.unmc.edu/surp2020/1002/thumbnail.jp